Diabetic Peripheral Neuropathy Type 2
Conditions
Keywords
Diabetic Peripheral Neuropathy, Stem Cell, TCSS, Type 2 diabetes mellitus
Brief summary
Diabetic Peripheral Neuropathy (DPN) is one of the most common chronic complications in type 2 diabetes, conventional drug therapy can only target a single pathogenesis but not treat Diabetic Peripheral Neuropathy (DPN) fundamentally. As a novel technique, stem cell transplantation provides a new option for patients with DPN. In 2012, Wuhan Central Hospital, took the lead in carrying out clinical research on the treatment of DPN with autologous bone marrow stem cells in China, and patients were significantly relieved. Based on this research, our clinical trial is to evaluate the safety and efficacy of HUC-MSCs in the treatment of refractory diabetic peripheral neuropathy (DPN) by formulating standard operating procedures (SOP) and quality standards (QS) to explore the possible mechanism of HUC-MSCs in the treatment of DPN.
Detailed description
As Diabetes is becoming a health problem of global concern rapidly, DPN, one of the common chronic complications in Diabetes is also getting more and more attention. The result of a survey of 5 regions in Southeast Asia showed that 39-72% of patients with DPN had severe or very severe impact on their quality of life. For the treatment of DPN, conventional drug therapy can almost only target a single pathogenesis and cannot treat it fundamentally. Therefore, new safe and effective treatment options for DPN are particularly important. Both here and abroad, large number of experimental studies have shown that Bone Marrow or Umbilical Cord Mesenchymal Stem Cells have a significant therapeutic effect on diabetic peripheral neuropathy. In 2012, the Department of Endocrinology of Wuhan Central Hospital took the lead in conducting a clinical study of Autologous Bone Marrow Stem Cells in the treatment of DPN in China. The results of the study showed that the nerve conduction velocity of the lower extremities in most patients was improved within 3 months after treatment compared with before treatment. No serious adverse events occurred during the period. Based on this research of our own. The clinical trial is to evaluate the safety and efficacy of HUC-MSCs in the treatment of refractory diabetic peripheral neuropathy (DPN) by formulating standard operating procedures (SOP) and quality standards (QS) to explore the possible mechanism of HUC-MSCs in the treatment of DPN. The investigators will do a Single center, randomization, open trial, controlled clinical trials design to assess treatment with the MSCs compared with the control group. 42 patients with DPN will be recruited in China. 21 patients receive i. m. HUC-MSCs both lower extremities (5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limbs). 21 patients in the control group received i.v. Lipoic Acid Injection (600 mg/d for 15 consecutive days). Both efficacy and Adverse Event (AE) during the 96 weeks follow up.
Interventions
BIOLOGICALHUC-MSCs
5 × 10\^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb
BIOLOGICALLipoic Acid
Lipoic Acid Injection，600 mg/d for 15 consecutive days
Sponsors
Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Hubei, China
Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, China
Wuhan Central Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Ages at 18-55 years (including 18 and 55 years), regardless of gender; * Understand and sign the ICF before proceeding with any steps related to this study, comply with the requirements, and do not to participate in other clinical studies during this research; * T2DM patients defined by the 2013 American Diabetes Association (ADA) standards; * Meet the diagnostic criteria for diabetic peripheral neuropathy: ① A clear history of diabetes; ② Neuropathy that occurs on or after the diagnosis of diabetes; ③Clinical symptoms and signs are consistent with DPN; ④ People with clinical symptoms (pain, numbness, abnormal sensation, etc.), had any 1 of the 5 items of ankle reflex, acupuncture pain, vibration, pressure and temperature in abnormal; people without clinical symptoms had any 2 of the 5 items were abnormal; * The evaluation of symptoms and signs of neuropathy is at severe level (TCSS score ≥12); * For conventional standard drug treatment (combined use of Lipoic Acid Capsules, Methyl cobalamin Tablets, and Epalrestat Tablets) at least 6 months and TCSS score decrease ≤30%;
Exclusion criteria
* Diseases that the investigator believes that it may interfere with subject compliance, including any uncontrolled diseases like in urinary, circulatory, respiratory, nervous, mental, digestive, endocrine, immune, and other system; * Pregnant women, breastfeeding women or those who have a childbearing plan soon; * Patients who are known to be allergic to cell products; * People with various types of malignancies or hematological diseases; * Complicated with severe lower extremity arterial disease (ankle-brachial index \< 0.9) * Complicated with foot ulcers, infections, or lower extremity amputation; * Combined with neuropathy caused by other causes, such as lumbar spondylosis, cerebral infarction, Guillain-Barre Syndrome, excluding severe arteriovenous vascular disease, application of some chemotherapy drugs or renal insufficiency, etc. Nerve damage disease; * Those who are unable or unwilling to provide informed consent or fail to comply with research requirements; * Participated in other stem cell clinical researches before enrollment; * Participated in other clinical trials within 3 months before enrollment. * Patients with positive serum HIV antibodies; * Patients with a history of alcohol and drug abuse and failed to abstain effectively
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of TCSS scale | Change from Baseline TCSS scale at week 24 | 1. Excellent: TCSS score decreased by \>30% compared with the baseline value after treatment; 2. Effective: TCSS score decreased by 30%-15% compared with the baseline value after treatment; 3. Ineffective: Those who did not achieve the standards above after treatment. |
| Change of nerve conduction velocities in the lower extremity | Change from Baseline nerve conduction velocities in the lower extremity at week 12 | 1. Excellent: after treatment, the lower extremity nerve conduction velocity and amplitude increased by more than 15% compared with the baseline value; 2. Effective: after treatment, the lower extremity nerve conduction velocity and amplitude increased by 15%-5% compared with the baseline value; 3. Ineffective: Those who did not achieve the standards above after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of serum inflammatory factors | Baseline, week 4, week 12, week 24, week 36, week 48, week 96 | Observe the changes during the study period |
| Change of growth factors (GF) | Baseline, week 4, week 12, week 24, week 36, week 48, week 96 | Observe the changes during the study period |
| Change of fasting plasma glucose (FPG) | Baseline, week 12, week 24, week 36, week 48, week 96 | Observe the changes during the study period |
| Change of glycosylated hemoglobin (HbA1c) | Baseline, week 12, week 24, week 36, week 48, week 96 | Observe the changes during the study period |
Countries
China
Contacts
Primary ContactWEI WEI
Outcome results
None listed